Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Actuate Therapeutics, Inc. Market Cap
Based on ratings from 0 stock analysts, the Actuate Therapeutics, Inc. stock price is expected to decrease by 100% in 12 months. This is calculated by using the average 12-month stock price forecast for Actuate Therapeutics, Inc.. The lowest target is $ and the highest is $. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned ACTU 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Actuate Therapeutics, Inc. to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ACTU. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ACTU.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
When did it IPO
N/A
Staff Count
11
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Daniel M. Schmitt
Market Cap
$139.8M
In 2023, ACTU generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ACTU's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Actuate Therapeutics (NASDAQ: ACTU) updated its Phase 1/2 trial of elraglusib for relapsed/refractory Ewing Sarcoma, focusing on therapies for difficult-to-treat cancers.
Why It Matters - Updates on clinical trials, especially for difficult-to-treat cancers, can influence stock prices, investor sentiment, and future funding opportunities for Actuate Therapeutics.
Thu, 05 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Actuate Therapeutics (NASDAQ: ACTU) will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, and will hold one-on-one meetings with investors.
Why It Matters - Actuate Therapeutics' participation in a major investment conference highlights its growth potential and engagement with investors, which could influence stock performance and market perception.
Sat, 17 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - This week saw two IPOs and three SPACs debut. HMH Holding filed to raise $100 million. Three IPOs from the Asia Pacific are scheduled next week, along with one SPAC pricing.
Why It Matters - Slow IPO activity indicates cautious investor sentiment and potential market volatility, while upcoming listings suggest opportunities for growth in the Asia Pacific region.
Wed, 14 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Actuate Therapeutics closed its IPO, offering 2.8 million shares at $8.00 each, raising $22.4 million. An option for underwriters to buy 420,000 additional shares is also available. Trading began on August 13, 2024, under "ACTU."
Why It Matters - Actuate Therapeutics' IPO raises $22.4 million, enhancing its financial position for cancer therapies. The market's reception and future funding potential are key indicators for investor sentiment.
Mon, 12 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Actuate Therapeutics, Inc. has priced its IPO at $8.00 per share, offering 2.8 million shares for total gross proceeds of $22.4 million.
Why It Matters - Actuate Therapeutics' IPO at $8 per share raises $22.4 million, signaling market confidence in its cancer therapies and providing capital for further development, impacting stock valuation and investor sentiment.
Sat, 03 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - In the first week of August, the U.S. saw one small IPO pricing, indicating a slow start to the month for initial public offerings.
Why It Matters - The limited IPO activity indicates a cautious market sentiment, potentially affecting liquidity and investment opportunities for investors seeking growth in new public companies.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
